Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... and a chromosome 5 alteration. 5- Azacitidine and decitabine have activity in higher risk MDS. 5-Azacitidine has been shown ...

    Research Article last updated 02/04/2014 - 1:37pm.

  2. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... and a chromosome 5 alteration. 5- azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown ...

    Research Article last updated 07/31/2012 - 2:02pm.

  3. Epigenetic therapy in myelodysplastic syndromes.

    ... of epigenetic modifiers, such as azacytidine and decitabine , trying to explain the biologic rationale for their use in this ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... and a chromosome 5 alteration. 5- azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Phase I, Dose Escalation Study of Decitabine

    ... Purpose:  Decitabine is a hypomethylating agent that has shown significant ... Leukemia (AML). This study is based on the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  6. Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

    ... This clinical trial studies decitabine and cytarabine in treating older patients with newly diagnosed ... neoplasm. Drugs used in chemotherapy , such as decitabine and cytarabine, work in different ways to stop the growth of cancer ...

    Clinical Trial last updated 04/21/2016 - 1:23pm.

  7. Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    ... to test the safety of the combination of omacetaxine and decitabine and to find the best dose to give to future patients. The goal ... Associated Drug(s):  Decitabine Phase:  Phase 2 ...

    Clinical Trial last updated 04/29/2016 - 11:19am.

  8. Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

    ... I/II trial studies the side effects and best dose of decitabine followed by mitoxantrone hydrochloride, etoposide, and ... as mitoxantrone hydrochloride, etoposide, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either ...

    Clinical Trial last updated 04/28/2016 - 9:51am.

  9. Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

    ... research study is to compare how 2 different drugs, decitabine and azacitidine , when given on a shorter than standard ... Azacitidine Decitabine Phase:  Phase 2 ...

    Clinical Trial last updated 04/28/2016 - 10:22am.

  10. Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

    ... and improving constitutional symptoms. Low dose decitabine has demonstrated depletion of DNMT1 in normal hematopoietic ... . Furthermore, the low toxicity associated with low dose decitabine would allow for more frequent (1 to 3 times weekly) administration ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.